SEC Form SC 13D/A filed by ADC Therapeutics SA (Amendment)
*
|
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
|
|
|
|
|
|
|
|
1
|
|
NAME OF REPORTING PERSON
A.T. Holdings II Sarl
|
||||
2
|
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ☐ (b) ☐
|
||||
3
|
|
SEC USE ONLY
|
||||
4
|
|
SOURCE OF FUNDS
WC
|
||||
5
|
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
☐
|
||||
6
|
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Switzerland
|
||||
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH:
|
|
7
|
|
SOLE VOTING POWER
0
|
||
|
8
|
|
SHARED VOTING POWER
2,231,210
|
|||
|
9
|
|
SOLE DISPOSITIVE POWER
0
|
|||
|
10
|
|
SHARED DISPOSITIVE POWER
2,231,210
|
|||
11
|
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
2,231,210
|
||||
12
|
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
☐
|
||||
13
|
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
2.7% (1)
|
||||
14
|
|
TYPE OF REPORTING PERSON
OO
|
(1)
|
Based on 82,814,000 common shares of ADC Therapeutics SA (the “Issuer”) outstanding as of April 12, 2024, as reported in the Issuer’s Preliminary Proxy Statement filed with the Securities
and Exchange Commission (“SEC”) on April 16, 2024.
|
|
|
|
|
|
|
|
1
|
|
NAME OF REPORTING PERSON
C.T. Phinco Sarl
|
||||
2
|
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ☐ (b) ☐
|
||||
3
|
|
SEC USE ONLY
|
||||
4
|
|
SOURCE OF FUNDS
AF
|
||||
5
|
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
☐
|
||||
6
|
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Luxembourg
|
||||
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH:
|
|
7
|
|
SOLE VOTING POWER
2,231,210
|
||
|
8
|
|
SHARED VOTING POWER
0
|
|||
|
9
|
|
SOLE DISPOSITIVE POWER
2,231,210
|
|||
|
10
|
|
SHARED DISPOSITIVE POWER
0
|
|||
11
|
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
2,231,210
|
||||
12
|
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
☐
|
||||
13
|
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
2.7% (1)
|
||||
14
|
|
TYPE OF REPORTING PERSON
OO
|
(1)
|
Based on 82,814,000 common shares of the Issuer outstanding as of April 12, 2024, as reported in the Issuer’s Preliminary Proxy Statement filed with the SEC on April 16, 2024.
|
|
|
|
|
|
|
|
1
|
|
NAME OF REPORTING PERSON
ADC Products Switzerland Sarl
|
||||
2
|
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ☐ (b) ☐
|
||||
3
|
|
SEC USE ONLY
|
||||
4
|
|
SOURCE OF FUNDS
WC
|
||||
5
|
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
☐
|
||||
6
|
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Switzerland
|
||||
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH:
|
|
7
|
|
SOLE VOTING POWER
0
|
||
|
8
|
|
SHARED VOTING POWER
2,228,085
|
|||
|
9
|
|
SOLE DISPOSITIVE POWER
0
|
|||
|
10
|
|
SHARED DISPOSITIVE POWER
2,228,085
|
|||
11
|
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
2,228,085
|
||||
12
|
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
☐
|
||||
13
|
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
2.7% (1)
|
||||
14
|
|
TYPE OF REPORTING PERSON
OO
|
(1)
|
Based on 82,814,000 common shares of the Issuer outstanding as of April 12, 2024, as reported in the Issuer’s Preliminary Proxy Statement filed with the SEC on April 16, 2024.
|
|
|
|
|
|
|
|
1
|
|
NAME OF REPORTING PERSON
Auven Therapeutics Holdings L.P.
|
||||
2
|
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ☐ (b) ☐
|
||||
3
|
|
SEC USE ONLY
|
||||
4
|
|
SOURCE OF FUNDS
AF
|
||||
5
|
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
☐
|
||||
6
|
|
CITIZENSHIP OR PLACE OF ORGANIZATION
British Virgin Islands
|
||||
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH:
|
|
7
|
|
SOLE VOTING POWER
0
|
||
|
8
|
|
SHARED VOTING POWER
2,231,210
|
|||
|
9
|
|
SOLE DISPOSITIVE POWER
0
|
|||
|
10
|
|
SHARED DISPOSITIVE POWER
2,231,210
|
|||
11
|
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
2,231,210
|
||||
12
|
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
☐
|
||||
13
|
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
2.7% (1)
|
||||
14
|
|
TYPE OF REPORTING PERSON
PN
|
(1)
|
Based on 82,814,000 common shares of the Issuer outstanding as of April 12, 2024, as reported in the Issuer’s Preliminary Proxy Statement filed with the SEC on April 16, 2024.
|
|
|
|
|
|
|
|
1
|
|
NAME OF REPORTING PERSON
Auven Therapeutics General L.P.
|
||||
2
|
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ☐ (b) ☐
|
||||
3
|
|
SEC USE ONLY
|
||||
4
|
|
SOURCE OF FUNDS
AF
|
||||
5
|
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
☐
|
||||
6
|
|
CITIZENSHIP OR PLACE OF ORGANIZATION
British Virgin Islands
|
||||
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH:
|
|
7
|
|
SOLE VOTING POWER
0
|
||
|
8
|
|
SHARED VOTING POWER
2,231,210
|
|||
|
9
|
|
SOLE DISPOSITIVE POWER
0
|
|||
|
10
|
|
SHARED DISPOSITIVE POWER
2,231,210
|
|||
11
|
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
2,231,210
|
||||
12
|
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
☐
|
||||
13
|
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
2.7% (1)
|
||||
14
|
|
TYPE OF REPORTING PERSON
PN
|
(1)
|
Based on 82,814,000 common shares of the Issuer outstanding as of April 12, 2024, as reported in the Issuer’s Preliminary Proxy Statement filed with the SEC on April 16, 2024.
|
|
|
|
|
|
|
|
1
|
|
NAME OF REPORTING PERSON
Auven Therapeutics GP Ltd.
|
||||
2
|
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ☐ (b) ☐
|
||||
3
|
|
SEC USE ONLY
|
||||
4
|
|
SOURCE OF FUNDS
AF
|
||||
5
|
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
☐
|
||||
6
|
|
CITIZENSHIP OR PLACE OF ORGANIZATION
British Virgin Islands
|
||||
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH:
|
|
7
|
|
SOLE VOTING POWER
0
|
||
|
8
|
|
SHARED VOTING POWER
2,231,210
|
|||
|
9
|
|
SOLE DISPOSITIVE POWER
0
|
|||
|
10
|
|
SHARED DISPOSITIVE POWER
2,231,210
|
|||
11
|
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
2,231,210
|
||||
12
|
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
☐
|
||||
13
|
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
2.7% (1)
|
||||
14
|
|
TYPE OF REPORTING PERSON
CO
|
(1)
|
Based on 82,814,000 common shares of the Issuer outstanding as of April 12, 2024, as reported in the Issuer’s Preliminary Proxy Statement filed with the SEC on April 16, 2024.
|
|
|
|
|
|
|
|
1
|
|
NAME OF REPORTING PERSON
Stephen Evans-Freke
|
||||
2
|
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ☐ (b) ☐
|
||||
3
|
|
SEC USE ONLY
|
||||
4
|
|
SOURCE OF FUNDS
AF
|
||||
5
|
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
☐
|
||||
6
|
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Ireland
|
||||
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH:
|
|
7
|
|
SOLE VOTING POWER
24,509.352705
|
||
|
8
|
|
SHARED VOTING POWER
2,231,210
|
|||
|
9
|
|
SOLE DISPOSITIVE POWER
24,509.352705
|
|||
|
10
|
|
SHARED DISPOSITIVE POWER
2,231,210
|
|||
11
|
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
2,255,719.352705
|
||||
12
|
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
☐
|
||||
13
|
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
2.7% (1)
|
||||
14
|
|
TYPE OF REPORTING PERSON
IN
|
(1)
|
Based on 82,814,000 common shares of the Issuer outstanding as of April 12, 2024, as reported in the Issuer’s Preliminary Proxy Statement filed with the SEC on April 16, 2024.
|
|
|
|
|
|
|
|
1
|
|
NAME OF REPORTING PERSON
Peter B. Corr
|
||||
2
|
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ☐ (b) ☐
|
||||
3
|
|
SEC USE ONLY
|
||||
4
|
|
SOURCE OF FUNDS
AF
|
||||
5
|
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
☐
|
||||
6
|
|
CITIZENSHIP OR PLACE OF ORGANIZATION
USA
|
||||
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH:
|
|
7
|
|
SOLE VOTING POWER
5,309.352705
|
||
|
8
|
|
SHARED VOTING POWER
2,231,210
|
|||
|
9
|
|
SOLE DISPOSITIVE POWER
5,309.352705
|
|||
|
10
|
|
SHARED DISPOSITIVE POWER
2,231,210
|
|||
11
|
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
2,236,519.352705
|
||||
12
|
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
☐
|
||||
13
|
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
2.7% (1)
|
||||
14
|
|
TYPE OF REPORTING PERSON
IN
|
(1)
|
Based on 82,814,000 common shares of the Issuer outstanding as of April 12, 2024, as reported in the Issuer’s Preliminary Proxy Statement filed with the SEC on April 16, 2024.
|
ITEM 4.
|
PURPOSE OF TRANSACTION
|
ITEM 5.
|
INTEREST IN SECURITIES OF THE ISSUER
|
|
|
|
Holder
|
|
Total Number of Common Shares
|
A.T. Holdings II
|
|
3,125 Common Shares (held by a nominee) over which A.T. Holdings II has voting and investment power
|
|
|
|
|
|
|
ADC Products
|
|
2,228,085 Common Shares
|
|
|
|
Stephen Evans-Freke |
24,509.352705 Common Shares |
|
Peter B. Corr |
5,309.352705 Common Shares |
ITEM 6.
|
CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER
|
|
A.T. HOLDINGS II SÁRL
|
||
|
By:
|
|
/s/ Stephen Evans-Freke
|
|
Name:
|
|
Stephen Evans-Freke
|
|
Title:
|
|
Managing Director
|
|
|
|
|
|
By:
|
|
/s/ Peter B. Corr
|
|
Name:
|
|
Peter B. Corr
|
|
Title:
|
|
Managing Director
|
|
C.T. PHINCO SÁRL
|
||
|
By:
|
|
/s/ Stephen Evans-Freke
|
|
Name:
|
|
Stephen Evans-Freke
|
|
Title:
|
|
Class A Manager
|
|
|
|
|
|
By:
|
|
/s/ Luis Tavares
|
|
Name:
|
|
Luis Tavares
|
|
Title:
|
|
Class B Manager
|
|
ADC PRODUCTS SWITZERLAND SÁRL
|
||
|
|
|
|
|
By:
|
|
/s/ Stephen Evans-Freke
|
|
Name:
|
|
Stephen Evans-Freke
|
|
Title:
|
|
Managing Director
|
|
By:
|
|
/s/ Peter B. Corr
|
|
Name:
|
|
Peter B. Corr
|
|
Title:
|
|
Managing Director
|
|
|
|
|
|
AUVEN THERAPEUTICS HOLDINGS L.P.
|
||
|
By:
By:
|
|
Auven Therapeutics General L.P., its general partner
Auven Therapeutics GP Ltd., its general partner
|
|
By:
|
|
/s/ Stephen Evans-Freke
|
|
Name:
|
|
Stephen Evans-Freke
|
|
Title:
|
|
Director
|
|
AUVEN THERAPEUTICS GENERAL L.P.
|
||
|
By:
|
|
Auven Therapeutics GP Ltd., its general partner
|
|
By:
|
|
/s/ Stephen Evans-Freke
|
|
Name:
|
|
Stephen Evans-Freke
|
|
Title:
|
|
Director
|
|
AUVEN THERAPEUTICS GP LTD.
|
||
|
|
|
|
|
By:
|
|
/s/ Stephen Evans-Freke
|
|
Name:
|
|
Stephen Evans-Freke
|
|
Title:
|
|
Director
|
|
|
|
|
|
By:
|
|
/s/ Stephen Evans-Freke
|
|
|
|
|
|
By:
|
|
/s/ Peter B. Corr
|